Drug intelligence / Profile preview

WD-01

Development stage: Phase 1
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies

Overview

WD-01 is an autologous CAR-T cell therapy under investigation for the treatment of metastatic colorectal cancer. This therapy involves genetically modifying a patient's own T cells with a second-generation Chimeric Antigen Receptor (CAR) that specifically targets Guanylyl Cyclase C (GCC) expressed on cancer cells. The therapy aims to assess the safety and efficacy, including objective response rate and progression-free survival, in patients with metastatic colorectal cancer.

Targets

GUCY2C (Guanylate cyclase C receptor)

Beyond the preview

Go deeper on WD-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WD-01.

Explore the full profile